TR200600315T1 - Östrojen replasman tedavisinin yan etkilerini hafifletmek için farmasötik bileşimler ve usul. - Google Patents

Östrojen replasman tedavisinin yan etkilerini hafifletmek için farmasötik bileşimler ve usul.

Info

Publication number
TR200600315T1
TR200600315T1 TR2006/00315T TR200600315T TR200600315T1 TR 200600315 T1 TR200600315 T1 TR 200600315T1 TR 2006/00315 T TR2006/00315 T TR 2006/00315T TR 200600315 T TR200600315 T TR 200600315T TR 200600315 T1 TR200600315 T1 TR 200600315T1
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
alleviating
side effects
replacement therapy
weight
Prior art date
Application number
TR2006/00315T
Other languages
English (en)
Inventor
Niedzwiecki Aleksandra
Rath Matthias
Ivanov Vadim
Netke Shrirang
Original Assignee
Rath Matthias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rath Matthias filed Critical Rath Matthias
Publication of TR200600315T1 publication Critical patent/TR200600315T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/32—Tin compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut buluş, menopoz sonrası bir kadındaki patolojik durumları hafifleten,lısın,prolin,argının, askorbık asit, magnezyum, yeşil çay ekstresı, N-asetıl-sısteın, selenyum, bakır, mangan ve bir taşıyıcı, seyreltıcı ve yardımcı maddeden oluşan gruptan seçilen farmasötık olarak uygun bir bileşen içerenfarmasotık bileşimler sağlamaktadır,burada bileşimler ağırlıkça %24-25 lısın, ağırlıkça %16-25 askorbık asit ve ağırlıkça %22-25 yeşil çay ekstresı içerir Aynca, farmasotık bileşimlerin kullanıldığı bir tedavi usulü tarif edilmektedir.
TR2006/00315T 2003-06-11 2004-06-11 Östrojen replasman tedavisinin yan etkilerini hafifletmek için farmasötik bileşimler ve usul. TR200600315T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/460,023 US20040253319A1 (en) 2003-06-11 2003-06-11 Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy

Publications (1)

Publication Number Publication Date
TR200600315T1 true TR200600315T1 (tr) 2006-08-21

Family

ID=33510922

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2006/00315T TR200600315T1 (tr) 2003-06-11 2004-06-11 Östrojen replasman tedavisinin yan etkilerini hafifletmek için farmasötik bileşimler ve usul.

Country Status (13)

Country Link
US (1) US20040253319A1 (tr)
EP (1) EP1638528A4 (tr)
JP (1) JP2007500754A (tr)
KR (1) KR20060063797A (tr)
CN (1) CN1997353A (tr)
AU (1) AU2004247145A1 (tr)
CA (1) CA2529225A1 (tr)
NO (1) NO20060143L (tr)
PL (1) PL379515A1 (tr)
RU (1) RU2006100031A (tr)
TR (1) TR200600315T1 (tr)
WO (1) WO2004110383A2 (tr)
ZA (1) ZA200600038B (tr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2524381A1 (en) * 2003-05-30 2004-12-16 Matthias Rath Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
US20070265211A1 (en) * 2006-05-12 2007-11-15 Matthias Rath Novel composition and method effective in inhibiting the atherogenic process
GB0624340D0 (en) * 2006-12-06 2007-01-17 Nature Therapeutics Ltd Antimicrobial composition
US20080319051A1 (en) * 2007-06-22 2008-12-25 Bionovo, Inc. Liquiritigenin and derivatives as selective estrogen receptor beta agonists
JP2013503135A (ja) 2009-08-26 2013-01-31 サノフイ 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
EP3873453A4 (en) * 2018-10-30 2022-08-03 University of Florida Research Foundation, Incorporated AMINO ACID COMPOSITIONS AND METHODS OF TREATING CYSTIC FIBROSIS
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
KR20210113716A (ko) 2020-03-09 2021-09-17 (주)아모레퍼시픽 성분 함량이 변화된 녹차 추출물을 포함하는 여성호르몬 조절 이상 질환 또는 증상의 예방, 완화, 개선 또는 치료용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4980358A (en) * 1988-04-04 1990-12-25 George D. McAdory Method employing gonadal hormones and dopamine agonist intended for combined use in the improvement of lymphocyte function
US5514382A (en) * 1994-10-17 1996-05-07 Sultenfuss; Sherry Daily vitamin and mineral supplement for women
US5569459A (en) * 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5654011A (en) * 1996-07-30 1997-08-05 Energetics, Inc. Dietary supplements
EP1068868A3 (en) * 1997-07-08 2001-01-31 Rath, Matthias, Dr. med. Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
US6086915A (en) * 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
CA2339473A1 (en) * 1998-08-04 2000-02-17 John V. Kosbab Nutrient and therapeutic compositions for the treatment of cancer
AU770075B2 (en) * 1999-02-24 2004-02-12 Mars, Incorporated Dietary compositions and methods
US6914073B2 (en) * 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
KR100379323B1 (ko) * 2000-02-29 2003-04-08 삼아약품 주식회사 카테킨을 포함하는 관상동맥 재협착 예방 및 치료용 약학조성물
US6476012B2 (en) * 2001-01-25 2002-11-05 Yale University Estradiol-16α-carboxylic acid esters as locally active estrogens
EA200301022A1 (ru) * 2001-03-16 2004-02-26 Уайт Гормональная заместительная терапия
ES2272555T3 (es) * 2001-12-14 2007-05-01 Matthias Rath Composicion de estrogeno y otras hormonas con ascorbato, lisina, prol ina y otras sustancias.
CA2471932A1 (en) * 2002-01-11 2003-07-17 Matthias Rath A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US7445807B2 (en) * 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement

Also Published As

Publication number Publication date
KR20060063797A (ko) 2006-06-12
JP2007500754A (ja) 2007-01-18
NO20060143L (no) 2006-03-07
EP1638528A4 (en) 2007-03-07
AU2004247145A1 (en) 2004-12-23
WO2004110383A3 (en) 2005-04-07
PL379515A1 (pl) 2006-10-02
ZA200600038B (en) 2007-03-28
US20040253319A1 (en) 2004-12-16
EP1638528A2 (en) 2006-03-29
RU2006100031A (ru) 2007-07-20
WO2004110383A2 (en) 2004-12-23
CA2529225A1 (en) 2004-12-23
CN1997353A (zh) 2007-07-11

Similar Documents

Publication Publication Date Title
TR200600315T1 (tr) Östrojen replasman tedavisinin yan etkilerini hafifletmek için farmasötik bileşimler ve usul.
IL173257A0 (en) Composition and method for facilitating bone healing
AU2003235762B2 (en) A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
JP6456383B2 (ja) イソチオシアネート系化合物と抗癌薬の併用
PT1687305E (pt) Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
MXPA05004526A (es) Derivados isoflavonoides aminados y usos de los mismos.
MXPA05004247A (es) Cromonas y derivados de cromona y usos de los mismos.
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
ME00428B (me) 5-hlor0-3-(4-metansulfonilfenil)-6'-metil-(2,3')bipiridinil u čistom kristalnom obliku i postupak sinteza
NZ596047A (en) Stabilized lipid formulation of apoptosis promoter
PL371205A1 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
JP2004519455A (ja) 脂質および／または骨密度の調節ならびにそのための組成物
JP2005325120A (ja) バクチオール含有薬剤組成物
WO2006124033A3 (en) Compositions and methods for reduction of cutaneous photoageing
FR2861594B1 (fr) Composition contenant un extrait de the vert et de la vitamine c
JP2005325119A (ja) バクチオール含有薬剤組成物
BRPI0414072A (pt) composição farmacêutica e seus usos para o retardo de doenças cardiovasculares
KR20170140995A (ko) 감국 꽃 추출물을 유효성분으로 함유하는 비만의 예방, 개선 또는 치료용 조성물
WO2006108430A8 (en) Nutrient composition comprising green tea polyphenols for treating osteosarcoma
Madonna et al. N, N-Bis-(8-hydroxyquinoline-5-yl methyl)-benzyl substituted amines (HQNBA): Peroxisome proliferator-activated receptor (PPAR-γ) agonists with neuroprotective properties
RU2005141423A (ru) Пищевые композиции и способ ингибирования ими сокращения гладкомышечной клетки
KR20090119085A (ko) 안토시아닌을 포함하는 자외선 조사에 의해 유도된아팝토시스 억제용 조성물
CY1110107T1 (el) Συνθεση για την ενεργοποιηση του ανοσοποιητικου συστηματος
KR100573246B1 (ko) 알파-리포익산 또는 디하이드로리포익산을 함유한골다공증의 예방 및 치료용 조성물
JP2018135287A (ja) 脳血管障害および／または認知症の予防、治療および／または症状進展抑制剤